Lilly, AbbVie, BMS and more rally against UK's 'arbitrary' growth cap on branded drug market

Even as pharma giants try to get a handle on the Inflation Reduction Act in the U.S., drug pricing tensions continue to flare overseas.

With the U.K. working to tweak the country's Statutory Scheme for branded medicines, the Association of the British Pharmaceutical Industry (ABPI) is making its discontent known—and the trade group has managed to rally more than 20 major drugmakers to its cause.